Zuther, Martin: An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity. - Bonn, 2010. - Dissertation, Rheinische Friedrich-Wilhelms-Universität Bonn.
Online-Ausgabe in bonndoc: https://nbn-resolving.org/urn:nbn:de:hbz:5N-21829
@phdthesis{handle:20.500.11811/4588,
urn: https://nbn-resolving.org/urn:nbn:de:hbz:5N-21829,
author = {{Martin Zuther}},
title = {An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity},
school = {Rheinische Friedrich-Wilhelms-Universität Bonn},
year = 2010,
month = sep,

note = {Classical Hodgkin’s lymphoma is one of the most curable cancers today. However, non-responders, tumour relapses and long-term toxicities of the treatment make it necessary to look for alternative drugs. In this study, we have generated a novel immunocytokine that aims to overcome the misguided TH2 immune response in Hodgkin’s lymphoma by targeting CD30 on the surface of the malignant Hodgkin-Reed-Sternberg cells, and by combining IL-2 and IL-12 domains in one molecule. This immunocytokine induces resting natural killer cells to specific lysis of CD30⁺ tumour cells, exhibits superior cytokine activity compared to immunocytokines with a single cytokine domain, and inhibits tumour growth in immunocompetent mice.},
url = {http://hdl.handle.net/20.500.11811/4588}
}

The following license files are associated with this item:

InCopyright